Canadian Cancer Trials Group Bulletins


CO.17 and Health-Related Quality of Life

Recently, Canadian Cancer Trials Group CO.17 demonstrated the antiepidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab improves overall and progression-free survival in patients with advanced, chemotherapy-refractory colorectal cancer (CRC), particularly in patients with wild-type KRAS tumors.

A recent article published online by JCO reports that cetuximab offers clinically important survival and HRQL benefits for pretreated patients with advanced CRC. These benefits are even greater in magnitude when cetuximab use is restricted to patients with wild-type KRAS status.

Following is the complete citation information:
Au H-J, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the Canadian Cancer Trials Group and AGITG CO.17 trial (ONLINE). J Clin Oncol 2009.